Risk of Bone Mineral Density Loss Associated with GLP-1 Receptor Agonists in Overweight COPD Populations [Letter] Authors: Yiwen Hong, Jia Liu Published: 2026 Dear editor Huang et al1 explored the cardioprotective and weight management benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the management of comorbidities in individuals with chronic obstructive pulmonary disease (COPD) and obesity, a distinct phenotype of respiratory comorbidities. Their article demonstrated that, among patients with coexisting COPD and obesity, the use of GLP-1RAs was significantly associated with lower mortality risk and a reduction in adverse respiratory and cardiovascular outcomes compared with other weight-loss medications. These findings have important clinical implications. However, before recommending GLP-1RAs for COPD patients with obesity, the following two points merit further discussion. Insufficient Evaluation of Osteoporosis-Related Risks First, although the study indicated that GLP-1RAs have positive effects on patients with COPD and obesity, including reductions in all-cause mortality, COPD exacerbations, acute respiratory failure, pneumonia, and cardiovascular events, it did not address the evaluation of osteoporosis or fracture-related risks, which may be a critical clinical issue for COPD patients. Patients with COPD are known to have an elevated risk of osteoporosis, resulting from a combination of factors such as chronic systemic inflammation, the use of inhaled or systemic corticosteroids, physical inactivity, and malnutrition. While the relationship between GLP-1RAs and bone health remains controversial, some studies have reported an increased risk of osteoporosis and fractures associated with their use. For example, evidence suggests that in older adults with type 2 diabetes, GLP-1RA use was associated with an 11% higher risk of fragility fractures compared to other antidiabetic drugs.2 Furthermore, in non-diabetic individuals, the rate of bone loss was significantly higher in those treated with GLP-1RAs compared with controls.3 In COPD patients with osteoporosis, bone loss and related pathological fractures (eg, hip fractures) can severely impact functional independence and long-term survival. Moreover, as GLP-1RAs are potent weight-loss agents, rapid weight reduction may further compromise bone density, exacerbating the progression of osteoporosis. Consequently, when balancing the potential pulmonary and cardiovascular benefits of GLP-1RAs, it is crucial to consider their impact on bone health, particularly in COPD patients with obesity and high osteoporosis risk. To better understand the role of GLP-1RAs in this distinct phenotype, we suggest incorporating osteoporosis-related factors, such as pathological fracture incidence and bone mineral density, into future study models. This would enable a more comprehensive assessment of both the benefits and risks of GLP-1RAs and provide solid grounds for clinical decision-making. Limitations in Follow-Up Duration and Characterization of All-Cause Mortality Second, while the study reported significant protective effects of GLP-1RAs on all-cause mortality, COPD exacerbations, and respiratory failure, two essential issues warrant further consideration: a. Limited characterization of patients with all-cause mortality: A more detailed analysis of the characteristics of patients with all-cause mortality is recommended. Identifying high-risk factors for mortality, such as fracture risks, and exploring their possible associations with GLP-1RAs could help ascertain whether the protective effects of GLP-1RAs on mortality risk are applicable to specific subgroups (eg, patients with osteoporosis). b. Short follow-up duration: In the current study, the median follow-up time was 530 days in the GLP-1RA group and 467 days in the control group. While this follow-up duration is suitable for the observation of short-term effects, it may underestimate the potential long-term adverse effects of GLP-1RA use. Notably, the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends reassessment of bone density in COPD patients every 3–5 years,4 indicating that changes in bone health often require longer periods to detect. Additionally, rapid weight loss and potential complications of osteoporosis may negatively influence long-term outcomes, and these risks can only be adequately evaluated with extended follow-up durations. Future studies are therefore encouraged to extend the follow-up period to ascertain whether the short- and long-term protective effects of GLP-1RAs are consistent and to evaluate their impacts on long-term health outcomes, such as bone health and all-cause mortality. In conclusion, GLP-1RAs have significant potential for use in patients with COPD and obesity, offering benefits such as weight reduction, improved cardiopulmonary function, and reduced all-cause mortality risk. However, the potential skeletal risks associated with osteoporosis and rapid weight loss warrant careful consideration. Further research should address this distinct phenotype to better inform comprehensive management strategies for comorbid COPD and obesity. Disclosure The authors report no conflicts of interest in this communication. References